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                                     INTRODUCTION
             Thalassemias represent the most common single gene disorder known. In 
many parts of the world, they constitute major public health problems. It occurs most 
frequently in people of Italian, Greek, Middle eastern, Asian and African ancestry.
              Beta Thalassemia is one of the commonest disorder affecting Indians.The 
incidence of Thalassemia is very high,over 250 million people carrying the defective 
gene  and  carrier  frequency  varies  from 3-17% in  various  populations.Ten  thousand 
Thalassemic children are born every year in India.A higher frequency is noted in certain 
communities like Sindhis,Panjabis,Baniyas from Gujarat and Gouda from Karnataka.
              It was first described by Thomas cooley and Pearl Lee in children of Italian 
origin1.Because all  early  cases were reported in children of  Mediterranean origin,the 
disease was later termed Thalassemia from the greek word for sea,”thalassa”2.        
        The thalassemia syndromes are a heterogeneous group of inherited anemias 
characterized by defects in the synthesis of one or more of the globin chain subunits of 
the hemoglobin tetramer.
                 The  most  common  forms  of  thalassemia  arise  from  total  absence  of 
structurally normal globin chains or a partial reduction in their synthesis. In contrast to 
the structural hemoglobinopathies (e.g., sickle cell anemia), which are characterized by 
the production of normal amounts of mutant globin chains having deranged physical or 
chemical properties, thalassemias are quantitative disorders: the primary lesion lies in 
the  amount  of  globin  produced.  However,  some  rare  forms  of  thalassemia  are 
characterized  by  the  production  of  structurally  abnormal  globin  chains  in  reduced 
amounts. These thalassemic hemoglobinopathies share features of both thalassemia and 
structural hemoglobinopathies.
           If  the  synthesis  of  alpha chains  is  suppressed,  level  of  all  three  normal 
hemoglobins-A1,A2  and  F  are  reduced  (alpha  Thalassemia).  If  beta  chains  are 
suppressed because of mutation in beta gene then production of adult  hemoglobin is 
suppressed (beta thalassemia) .                  
            Two genes control the production of beta globin.Mutations of one or both 
of  them can cause  the  disorder.There  are  three  main  forms  of  beta  thalassemia.The 
severity of the condition is determined by whether one or both globin genes are mutated 
and by the severity of mutation.
              By the age of 6 to 12 months, most affected infants show pallor, irritability, 
growth  retardation,  jaundice,  and  hepatosplenomegaly  as  a  result  of  extramedullary 
hematopoiesis.  By 2 years  of  age,  90% of infants  are  symptomatic,  and progressive 
changes in the facial and cranial bones develop.
            More than 80% of children with homozygous thalassemia require regular 
RBC transfusions by 1 to 2 years of age because of severe anemia. Life expectancy with 
untreated thalassemia major is less than 5 years. Outcomes of the patients with poorly 
transfused thalassemia major reflected severe anemia and compensatory hypertrophy of 
medullary and extramedullary erythroid tissue in attempt to compensate for the anemia.
             Many of the features of Thalassemia become less severe with transfusion 
therapy. But creation of excessive iron stores associated with hemosiderosis is a major 
concern  in  individuals  with  beta  Thalassemia  and  many  of  the  complications  of 
Thalassemia  are  the  result  of  increased  iron  deposition  from  repeated  blood 
transfusions.Iron  released  from  the  breakdown  of  endogenous  or  transfused  RBCs 
cannot  be  utilized  for  hemoglobin  synthesis.  This  iron  is  eventually  deposited 
(hemosiderosis) in various organs e.g-liver, spleen, heart, endocrine glands leading to 
their malfunction.. At a total body iron burden of 40 g, organ function begins to fail, and 
at 60 g or more, intractable cardiac failure has its onset.  
          The liver is a major repository of transfused iron.Hepatic parenchymal iron 
accumulation, demonstrated after only 2 years of transfusion therapy, may rapidly result 
in portal fibrosis in a significant percentage of patients. One center has observed portal 
fibrosis in a high percentage of biopsies in children under the age of 3 years. In young 
adults with thalassemia major, in whom liver disease remains a common cause of death, 
viral infection may act synergistically with iron in accelerating the development of liver 
damage.  Managing  iron  overload  in  Thalassemia  syndromes  require  a  reliable 
assessment of excessive iron overload and organ iron distribution.
         Measurement  of  hepatic  iron  concentration  is  the  most  quantitative, 
specific,  and sensitive method for determining the body iron burden in patients with 
thalassemia  major.  Liver  biopsy   permits  chemical  measurement  of  the  nonheme 
(storage)  iron  concentration  and  histochemical  examination  of  the  pattern  of  iron 
accumulation in hepatocytes and Kupffer cells as well  as evaluation of the extent of 
inflammation, fibrosis, and cirrhosis. These direct methods for assessing iron status have 
the disadvantages of being invasive procedures, with their attendant discomfort, lack of 
acceptability to patients, and, in the case of liver biopsy, risk.
             Several  noninvasive  means  of  measuring  tissue  iron  stores  include 
determination  of  hepatic  magnetic  susceptibility,  computed  tomography  (CT),  and 
magnetic  resonance  imaging  (MRI).  As  serum ferritin  is  the  most  commonly  used 
parameter for judging iron overload  the present study  was done to determine whether 
sigificant  correlation  exists  between  serum  ferritn  and  CT  liver  density.  CT  was 
preferred to MRI in the present study as it is more widely available and less expensive.
                                                 
REVIEW OF LITERATURE
                      
Thalassemia major
Homozygosity  for  thalassemia  genes  is  usually  associated  with severe  anemia 
because of  a  marked reduction of  synthesis  of  the globin chains of  HbA. However, 
reduction  of  HbA  synthesis  does  not  explain  the  hemolysis  and  ineffective 
erythropoiesis  that  are  consequences  of  unbalanced globin  chain  synthesis.  In 
homozygous  thalassemia,  alpha  globin  chains  are  produced  in  normal  amounts  and 
accumulate, denature, and precipitate in the RBC precursors in the bone marrow and 
circulating RBC. These precipitated alpha globin chains damage the RBC membrane, 
resulting in destruction within the bone marrow (ineffective erythropoiesis) and in the 
peripheral blood.
 By the age of 6 to 12 months,  most  affected infants show pallor,  irritability, 
growth  retardation,  jaundice,  and  hepatosplenomegaly  as  a  result  of  extramedullary 
hematopoiesis.  By 2 years  of  age,  90% of infants  are  symptomatic,  and progressive 
changes in the facial and cranial bones develop. The hemoglobin level may be as low as 
30 to 50 g/L. 
           The  natural  course  of  thalassemia  major  is  one  of  recurrent  infections, 
progressive  cachexia,  and  death  by  5  years  of  age.  Aggressive  transfusion  therapy 
permits  near-normal  growth  and  development  in  childhood  but  itself  produces 
progressive organ damage with death from iron overload in adolescence or early adult 
life.  With  transfusion  therapy,  approximately  25% of  patients  survived  to  their  mid 
twenties. Still, nearly two-thirds die with complications of myocardial hemosiderosis at 
a  mean  age  of  16  to  17  years.  The  transfusional  iron  overload  is  compounded  by 
increased  intestinal  absorption  of  iron  is  suggested  by  the  observation  that  the  iron 
present  at  autopsy  exceeds  that  which  can  be  accounted  for  by  transfusions  alone. 
Enhanced iron absorption has been confirmed by direct measurement. The introduction 
of iron chelation therapy in the 1970s constituted a further therapeutic advance. In one 
series, the median age of survival was 31 years3.The most important factors associated 
with survival were the age at which chelation therapy was introduced and the success 
with which serum ferritin was maintained below 2500 ng/ml4.
          The symptomatic thalassemia syndromes are predictably complicated by tissue 
iron toxicity. Avoidance of unnecessary iron exposure is of paramount importance. As in 
association  with  other  chronic  hemolytic  anemias,  folate  supplementation  may  be 
necessary.The  hepatitis  B  vaccine  is  recommended  for  all  patients  before  starting 




          In the past, transfusions were given only for the temporary relief of symptoms 
caused by severe anemia. This practice was based on the premise that the restriction of 
blood  administration  would  delay  the  onset  of  transfusional  hemosiderosis.  Because 
erythropoiesis was not suppressed, the numerous complications resulting from exuberant 
erythroid hyperplasia persisted.  Survival  into the second decade was achieved at the 
expense of progressive facial and skeletal deformities, osteoporosis, and splenomegaly. 
          Later, transfusion programs designed to maintain the minimum hemoglobin 
concentration above 10 g/dl and the mean hemoglobin concentration at 12 g/dl improved 
the quality of life without accelerating the lethal complications of iron overload5. Such 
hypertransfusion  programs  effectively  suppress  erythroid  activity  and  prevent  the 
unlimited bone marrow expansion that underlies the skeletal pathology of thalassemia 
major.
          When begun early in life, transfusions prevent the facial stigmata of thalassemia 
and facilitate normal growth during the first  decade6.  Growth usually is permanently 
delayed if normal levels of hemoglobin are not maintained until after the child is three or 
4 years of age7. Even in optimally transfused patients, growth begins to deviate from the 
normal curve at 10 to 13 years and subsequent sexual  development is  delayed, both 
consequences of iron overload8. Additional advantages of a regular transfusion program 
include  prevention  or  delay  in  the  development  of  congestive  splenomegaly,  fewer 
severe infectious illnesses, and improved cardiac reserve9. Fortunately, the concern that 
a more aggressive transfusion program would accelerate iron overload and lead to death 
at an earlier age has not been realized. Failure to observe a deleterious impact of the 
more  liberal  use  of  blood  on  survival  is  attributed  to  suppression  of  excessive 
gastrointestinal iron absorption by maintenance of a normal hemoglobin concentration.
          Because  bone  marrow  mass  and  blood  volume  remain  expanded  with 
hypertransfusion, a more aggressive program of transfusion (supertransfusion) has been 
advocated by some10. Maintenance of a mean hemoglobin value of 14 to 15 g/dl almost 
completely suppresses endogenous erythropoiesis, thereby shrinking the bone marrow 
mass and reducing the blood volume by approximately 20%11. Reduction of the blood 
volume, in turn, permits the maintenance of a higher hemoglobin concentration without 
an increase in the transfusion requirement. Within 1 to 4 months of raising the minimum 
hemoglobin  value  to  12  g/dl,  the  transfusion  requirement  returns  to  that  amount 
necessary to maintain a minimum level of 9 g/dl12. The effect of supertransfusion on 
growth and development during the second decade remains to be evaluated.
          The use of young red cells (neocytes) may reduce the total blood requirement. 
Collection  of  neocytes  by  continuous  flow  centrifugation   or  by  fractionation  of 
conventionally collected blood with a blood cell processor  is feasible. Selective removal 
of the least dense fraction yields a population of cells that have a mean age of 12 to 21 
days and a half-survival time of 40 to 47 days in contrast to 29 days for standard frozen 
cells.  Unfortunately,  the  reduction  in  blood  requirements  during  extended  trials  of 
neocytes is substantially less than predicted1.           
          The complete genotype of patient red cells should be determined before the first 
blood  transfusion  is  given.  This  information  may  prove  invaluable  for  identifying 
compatible  blood   should  antibodies  to  minor  blood  group  antigens  develop.  It  is 
recommended that blood be administered through a leukofilter to minimize the risk of 
febrile reactions that result from the development of antibodies to white blood cells.
Iron Chelation 
          Most patients with thalassemia major die from complications of iron overload. At 
a total body iron burden of 40 g, organ function begins to fail, and at 60 g or more, 
intractable cardiac failure has its onset. In recent years, concerted and aggressive steps 
have been taken to reckon with this inevitable complication.
          The most effective iron chelating agent widely available is deferoxamine, a 
siderophore produced by Streptomyces pilosus14. Experience with the use of this drug 
for  rectifying transfusional iron overload has been reviewed. Iron excretion after the 
administration  of  deferoxamine  is  proportional  to  body  iron  stores.  In  patients  with 
thalassemia  major  who  are  begun  on  regular  transfusions  in  the  first  year  of  life, 
mobilization of  clinically  significant  amounts  of  iron cannot  be achieved with daily 
intramuscular injections of deferoxamine until five to ten years of age, and negative iron 
balance is achieved infrequently at any age15. Nevertheless, chronic chelation therapy 
begun in the first decade of life reduces hepatic iron levels, retards the progression of 
hepatic fibrosis, and facilitates continued growth. Unfortunately, it appears to have little 
effect on the endocrine and cardiac complications of hemosiderosis16. 
          When given by continuous intravenous or subcutaneous infusion, deferoxamine 
sustains  a  greater  urinary  excretion  of  iron17.  The  greater  efficiency  of  continuous 
infusions of the drug is thought to relate to the constant exposure of a labile iron pool to 
the chelating agent. The relationship between iron excretion and deferoxamine infused is 
linear to a dose of 1.5 to 2.0 g/24 hours. In some heavily iron-loaded patients, a linear 
response continues to 4, 8, or even 16 g/24 hours. The requisite amount of drug is given 
most  conveniently  with  a  small  portable  infusion  pump  that  permits  delivery  of 
microliter  quantities  of  the  drug  subcutaneously  from a  standard  syringe  through  a 
butterfly needle placed by the patient in the anterior abdominal wall. The total daily dose 
is infused over an 8 to 12-hour period at night, allowing freedom from the device during 
daylight hours. Limited experience with high-dose deferoxamine (6 to 12 g daily) given 
intravenously suggests that it may be superior to conventional subcutaneous therapy in 
heavily iron overloaded patients18.
          Institution of chelation therapy before 10 years of age preserves gonadal function 
and facilitates normal sexual maturation in most patients1. Because the major cause of 
death in thalassemia patients relates to myocardial hemosiderosis, the value of chelation 
therapy  ultimately  is  determined  by  its  success  in  preventing  or  reversing  cardiac 
disease. Although relevant data are limited, chronic deferoxamine infusions appear to 
prevent or delay the development of heart disease in heavily transfused patients.
          Current efforts are directed at the prevention rather than the treatment of iron 
overload.  It  is  recommended  that  deferoxamine  be  started  after  the  first  10  to  20 
transfusions, or when the serum ferritin reaches 1000 ng/mL. In general these criteria are 
reached at about 3 years of age. Infusions started at this age can maintain iron balance. 
Needle  biopsy  of  the  liver  with  quantitation  of  liver  iron  permits  a  more  accurate 
measurement of body iron burden. Those who have used this approach recommend that 
chelation therapy be started as hepatic iron concentration approaches 9 µm iron per gram 
liver, wet weight, or 1.5 mg iron per gram liver, dry weight. This can occur as early as 1 
year after the beginning of regular transfusions.
          When given before 3 years of age, deferoxamine must be given at a reduced dose 
(20 to 30 mg/kg/day) to prevent the drug's adverse effect on linear growth. After 3 years 
of age, the dose of deferoxamine may be increased to 40 to 50 mg/kg/day. Doses of 
deferoxamine in excess of 50 to 60 mg/kg/day are associated with visual and auditory 
neurotoxicity . Sudden deterioration in pulmonary function, possibly immune-mediated, 
has been observed shortly after the institution of deferoxamine in some patients.
          The efficacy of a properly executed program of iron chelation in preventing iron 
accumulation is well documented.Failure to maintain the serum ferritin below 2500 ng/
mL or the total  body iron burden below 1 g/kg were adverse prognostic factors  for 
survival  .  Heart  failure,  diabetes  mellitus,  and  early  death  are  prevented  when 
deferoxamine  is  begun  at  an  early  age  and  given  in  amounts  proportional  to  the 
transfusion-related iron load.
          Ascorbic acid appears to render tissue iron more accessible to deferoxamine, 
thereby  enhancing  total  iron  excretion  without  increasing  iron  absorption.  The  net 
amount of iron excreted by iron-overloaded subjects receiving deferoxamine is increased 
twofold by the daily oral administration of 200 to 500mg ascorbic acid. Unfortunately, 
ascorbate also increases the toxicity of tissue iron. Sudden deterioration of heavily iron-
loaded patients given both deferoxamine and ascorbic acid is well documented.20 
          Deferoxamine is expensive and its administration is so cumbersome as to invite 
noncompliance.  A safe  and effective chelating agent  that  can be  taken by mouth is 
needed  badly.  Deferiprone  (1,2-dimethyl-3-hydroxypyridin-4-one)  is  the  most 
promising. In a pilot study of patients unable or unwilling to use deferoxamine, oral 
deferiprone was reported to induce a sustained decrease in body iron. In randomized 
trials comparing deferiprone and deferoxamine, however, a 50% increase in hepatic iron 
was observed after 2 years in patients given the oral chelator, whereas no significant 
accumulation of iron was detected in those receiving deferoxamine. Long term therapy 
with  deferiprone  may  not  provide  the  needed  control  of  body  iron  in  a  significant 
proportion of chronically transfused patients. Reversible agranulocytosis and arthralgias 
are infrequent complications of deferiprone. 
ICL 670 is an orally active chelating agent developed for the treatment of iron 
overload.It represents a new class of tridentate iron chelators with a high specificity for 
iron. Phase III trials are completed. There are no major safety concerns at doses upto 80 
mg/kg/day.  Iron excretion is dose dependent and is almost entirely in the feces.The 
plasma half life (11-19 hours) supports the once daily oral dosing regimen.              
Laboratory Evaluation of Iron Status  
Body iron supply and stores may be evaluated by both direct and indirect means, 
but no single indicator or combination of indicators is ideal for the evaluation of iron 
status in all clinical circumstances. As body iron content decreases from the iron-replete 
normal to the amounts found in iron deficiency anemia, or increases to the magnitudes 
found  in  iron  overload,  each  available  measure  reflects  in  a  different  manner  the 
continuum of changes shown in. In addition, each indicator may be affected by other 
conditions, such as infection, inflammation, liver disease, malignancy, or malnutrition, 
and must be interpreted with an awareness of the potential influence of such coexisting 
disorders.
Direct Measures
           The direct measures of body iron status yield quantitative, specific, and sensitive 
determinations of body or tissue iron stores. Quantitative phlebotomy provides a direct 
measure of total mobilizable storage iron. Repeated venesection to remove about 500 ml 
of blood weekly is performed until the hemoglobin concentration falls to <10 g/dl for 2 
weeks without further phlebotomy. Mobilizable storage iron may then be calculated as 
the amount of hemoglobin iron removed, with corrections for the hemoglobin deficit and 
estimated GI iron absorption during the course of phlebotomy. Quantitative phlebotomy 
is  inapplicable  to most  anemic disorders but  is  occasionally  useful  in the diagnostic 
evaluation  of  some forms of  iron overload,  for  example,  in  patients  with hereditary 
hemochromatosis who do not undergo liver biopsy.
           Bone  marrow aspiration  and  biopsy  can  provide  information  about  (1) 
macrophage storage iron, by semiquantitative grading of marrow hemosiderin stained 
with Prussian blue, or if needed, by chemical measurement of nonheme iron; (2) the iron 
supply  to  erythroid  precursors,  by  determining  the  proportion  and  morphology  of 
marrow sideroblasts (i.e., normoblasts with visible aggregates of iron in the cytoplasm); 
and (3) the general morphologic features of hematopoiesis. Bone marrow aspiration and 
biopsy  are  useful  in  studies  of  iron  deficiency  but  of  limited  applicability  in  the 
evaluation of iron overload because no information about the extent of parenchymal iron 
deposition is provided.
           In the evaluation of iron overload, liver biopsy is the best direct test for assessing 
iron deposition, permitting quantitative measurement of the nonheme iron concentration 
and histochemical examination of the pattern of iron accumulation in hepatocytes and 
Kupffer cells as well as evaluation of the extent of inflammation, fibrosis, and cirrhosis.
           These direct methods for assessing iron status have the disadvantages of being 
invasive procedures, with their attendant discomfort, lack of acceptability to patients, 
and, in the case of liver biopsy, risk. Several noninvasive means of measuring tissue iron 
stores include determination of hepatic magnetic susceptibility, computed tomography 
(CT), and magnetic resonance imaging (MRI).
Indirect Measures
           The indirect measures of body iron status have the advantages of ease and 
convenience, but all are subject to extraneous influences and lack specificity, sensitivity, 
or both. The measurement of plasma ferritin provides the most useful indirect estimate 
of body iron stores. 
Twenty-four-hour deferoxamine-induced urinary iron excretion
           The usefulness of measurement of the amount of chelated iron in the urine 
induced  by  a  single  intramuscular  dose  or  prolonged  subcutaneous  infusion  of 
deferoxamine has several limitations in the accurate assessment of body iron burden. 
Most important is the poor correlation between urinary iron excretion and hepatic iron 
concentration, in part because the relative amounts of iron excreted into stool and urine 
vary  with  the  dose  of  deferoxamine  administered,  body  iron  burden,  and  erythroid 
activity.  Chelator-induced  urinary  iron  excretion  is  also  vulnerable  to  extraneous 
influences by infection, inflammation, the activity and effectiveness of erythropoiesis, 
extramedullary hematopoiesis, liver disease, and ascorbic acid deficiency.
Serum ferritin
           Ferritin is found in virtually all cells, providing both an accessible reserve of iron 
for synthesis of functional iron-containing compounds and a means of sequestering iron 
in a soluble, apparently nontoxic form. It is especially abundant in cells with specialized 
roles in the synthesis of iron-containing compounds (erythroid precursors) and in iron 
metabolism and storage (macrophages, hepatocytes). 
           Intracellular ferritin is synthesized by the smooth endoplasmic reticulum in 
amounts  required  to  replace  catabolized  ferritin  and  hemosiderin  and  to  store  any 
additional  iron entering the cell.  Small  amounts of ferritin are also secreted into the 
plasma.Plasma ferritin is  apparently synthesized by the rough endoplasmic reticulum 
and glycosylated by the Golgi apparatus.
           Under normal circumstances, the amount of plasma ferritin synthesized and 
secreted seems to  be proportional  to  the amount  of  cellular  ferritin  produced in  the 
internal iron storage pathway, so that the plasma ferritin concentration is related to the 
magnitude of body iron stores. The small amounts of ferritin secreted into the circulation 
can  be measured by immunoassay and have a  logarithmic  relationship to  body iron 
stores  in  normal  individuals.  In  the  absence  of  complicating  factors,  plasma ferritin 
concentrations decrease with depletion of storage iron and increase with storage iron 
accumulation.
           Increased plasma ferritin concentrations may indicate increased iron stores, but a 
number of disorders may raise the plasma ferritin level independently of the body iron 
store.  Plasma ferritin  is  an acute  phase reactant,  increased ferritin  synthesis  being a 
nonspecific  response  that  is  part  of  the  general  pattern  of  the  systemic  effects  of 
inflammation.  Thus,  fever,  acute  infections,  rheumatoid  arthritis,  and  other  chronic 
inflammatory disorders elevate the plasma ferritin concentration. Both acute and chronic 
damage to the liver, as well as to other ferritin-rich tissues, may increase plasma ferritin 
as an inflammatory process or by releasing tissue ferritins from damaged parenchymal 
cells; these tissue ferritins are not glycosylated.
           De Virgilis21 et al studied serum ferritin, liver iron stores, and liver histology in 
38  children  with  thalassaemia  major  who  were  being  treated  by  regular  blood 
transfusions.  In  the study it  was noted that  there  was no correlation between serum 
ferritin levels and either the number of transfusions or the amount of iron deposited in 
the liver. However, for a given level of iron stores, ferritin levels were higher in patients 
with chronic hepatitis (including chronic aggressive and chronic persistent forms) than 
in those with hepatic siderosis only. It was concluded that serum ferritin reflects tissue 
iron  deposits  in  regularly  transfused  thalassaemic  patients,  only  in  the  absence  of 
hepatitis.
           In a study done by Letsky et al 22 the effect of iron chelation treatment on iron 
overload  has  been  assessed  by  estimating  serum  ferritin  levels  and  liver  iron 
concentrations in both chelator-treated and control groups. When compared with non-
chelated controls, results of both these estimations were invariably lower in the chelated 
group. However, all the results in both groups were very high, and fell within the ranges 
observed  in  untreated  idiopathic  haemochromatosis.They  found  a  close  correlation 
between  serum  ferritin  levels  and  liver  iron  concentrations  in  regularly  transfused 
children on continuous chelation therapy,  indicating that  serum ferritin is  a valuable 
alternative to liver iron concentration in the assessment of visceral iron overload, even 
when massive tissue siderosis is present.
           Bonkovsky et al23 did a study and compared the results of imaging procedures 
with those  of  other  noninvasive  techniques  and liver  biopsies  in  48 patients.  Serum 
ferritin and computed tomography or magnetic resonance scanning had 100% sensitivity 
in detecting hepatic iron overload more than fivefold above the upper limit of normal 
(greater than 10.7 µmol Fe/100 mg dry liver) but did not detect lesser degrees of iron 
overload reliably. Computed tomography and magnetic resonance imaging were more 
specific than ferritin (64% and 92% vs. 21%) in the detection of iron excess, more than 
five times the upper limit of normal.  It was concluded that computed tomography or 
magnetic resonance scanning as currently usually used is not cost-effective in routine 
evaluation  of  iron  overload,  although  these  imaging  procedures  may  play  a  role  in 
patients in whom liver biopsy is contraindicated. Because of their low cost and ready 
availability, serum ferritin remain the preferred screening study for iron overload. 
MRI
           Gomori et al24 in their study found that Quantitative MR imaging is a readily 
available noninvasive method for the assessment of hepatic iron concentration in iron-
overloaded patients, reducing the need for needle biopsies of the liver.              
CT liver density   
           In a study done by Bell et al26 Computed tomography (CT) was performed to 
estimate  the  density  of  the  hepatic  and  splenic  parenchyma  in  18  patients  with 
hemochromatosis.They found an  association between CT density and serum ferritin (r = 
0.72,  p  <  0.01).  The  difference  in  density  between  liver  and  spleen  gave  better 
discrimination  between  patients  and  controls:  12  of  18  (67%)  showed  an  increased 
difference in density between liver and spleen.
          A study was done by Howard et al26 to determine whether or not hepatic computed 
tomography  density  is  an  alternative  to  liver  biopsy  for  the  diagnosis  of  body  iron 
overload.Hepatic  computed  tomography  density  was  determined  in  healthy  controls, 
patients with idiopathic hemochromatosis, and patients with liver disease. An elevated 
hepatic  computed  tomography  density  associated  with  an  elevated  serum  ferritin 
indicates iron overload; When computerized tomography is applied to patients with an 
unexplained elevation of the serum ferritin, it provides a noninvasive alternative to liver 
biopsy for the detection of excess hepatocellular iron.
          JS Mitnick et al27 reported the striking increase in lymph node density due to 
hemochromatosis  observed  with  computed  tomography  (CT)  in  nine  patients  with 
Cooley  anemia  treated  with  multiple  blood  transfusions.  The  CT  appearance  and 
pathologic findings of hemochromatosis of the liver and spleen in three of these patients 
were also observed and correlated with pathologic specimens. CT density of the liver 
seemed to relate to the degree of hepatic fibrosis or cirrhosis, rather than the amount of 
iron. 
           Guvader et al28  did a study to evaluate the effectiveness of single-energy 
computed tomography in determining iron overload in idiopathic hemochromatosis, with 
special reference to slightly overloaded cases. Liver attenuation was determined in 100 
patients (46 cases of idiopathic hemochromatosis, 32 cases of chronic liver disease, and 
22  normal  controls).  The  iron  load  was  determined  for  the  first  two  groups  by 
biochemical determination of liver iron concentration (performed in all but 12 subjects 
in the chronic liver disease group) and hepatic histologic grading. The main results for 
liver attenuation (upper normal limit, 72 Hounsfield units) showed that despite a high 
specificity  (0.96),  this  parameter  was of  low sensitivity  (0.63).  Although mean liver 
attenuation in idiopathic hemochromatosis (77 +/- 14) was significantly higher than in 
chronic liver diseases (53 +/- 17; p less than 10(-4) and normal controls (66 +/- 3; p less 
than 10(-3], and despite an overall good correlation between liver attenuation and liver 
iron concentration (r = 0.72; p less than 10(-3], liver attenuation was unable to detect 
moderate iron overload. Fourteen of 18 patients with a liver iron concentration of less 
than 150 µmol/g dry liver wt had liver attenuation values of less than 72. Moreover, 3 of 
18 subjects with a liver iron concentration of greater than 150 had a liver attenuation of 
less  than  72.  Of  these  17  false-negatives,  only  7  could  be  attributed  to  associated 
steatosis. On the whole, single-energy computed tomography, when used on a routine 
basis  for  diagnosing  iron  overload,  is  of  limited  clinical  value  in  idiopathic 
hemochromatosis due to its  poor sensitivity.  Hepatic histologic  examination together 
with biochemical determination remains the most accurate means to assess liver iron.
           In a study done by Houang et al29 Computer tomographic (CT) scans of the liver 
were obtained in six thalassaemic patients with iron overload confirmed by liver biopsy. 
Mean CT values for the liver in individual  patients were linearly related to the iron 
content estimated by liver biopsy (correlation coefficient = 0.995).
           In a study done by Babiker et al30 thirty-seven children with beta-thalassaemia 
major, eight children with liver cirrhosis, and 20 matched controls were enrolled. Serum 
ferritin was determined in each subject by radio-immunoassay and liver enzymes by 
standard methods. The liver, spleen, kidney and pancreas densities were obtained by 
computed tomography. The iron content of liver biopsies from 10 patients was graded 
by  staining.  The  mean  serum ferritin  of  the  thalassaemic  patients  was  significantly 
higher than that of the control group (p = 0.0001). The ferritin of patients with cirrhosis 
and Wilson's disease was similar to that of the control group. The liver density of the 
thalassaemic patients was significantly higher than that of the control group (p less than 
0.0001) while that of patients with liver cirrhosis and Wilson's disease was similar to the 
control  group.  The liver  iron content  of  patients  with liver  cirrhosis  was within the 
normal range. The spleen and kidney densities of patients with thalassaemia were higher 
than that of the control group with p values of 0.02 and 0.056, respectively. The density 
of the pancreas in patients with thalassaemia was not significantly different from that of 
the control group, (p = 0.52). There was correlation between the liver density and serum 
ferritin in patients with thalassaemia (r = 0.432, p less than 0.01) while there was no 
correlation between spleen, pancreas and kidney densities with serum ferritin.
           In a study done by Guvader et al31 it was found that Serum iron and transferrin 
saturation are poorly correlated with the degree of iron overload.  Serum ferritin is a 
better reflect of iron stores but numerous clinical conditions, unrelated to variations of 
iron load, can increase the serum level. Biochemical determination of liver iron overload 
is the gold standard of iron quantification and well correlated to the level of iron burden 
appreciated  by  the  amount  of  iron  removed  by  venesection,  but  its  determination 
necessitates a liver biopsy and is dependant of sampling error in case of heterogeneous 
iron deposits (cirrhosis). The sensitivity of computed tomography is insufficient, being 
unable to detect iron overload below 5 times the normal liver iron load, especially in 
case of associated steatosis. Magnetic resonance imaging is a valuable tool when using 
T2 weighted gradient echo sequences on 1.5 Tesla magnet and permits non invasive iron 
overload quantification.
           In  the  study  done  by Gomori  et  al,  the  authors  assessed  the  use  of  T2 
measurements  obtained by means of  MR imaging as  well  as  computed tomographic 
(CT) attenuation as a measure of liver iron concentration in 10 severely iron-overloaded 
patients with beta- thalassemia major. 
The  iron concentrations  in  surgical  wedge  biopsy  samples  of  the  liver,  which 
varied between 3 and 9 mg/g of wet weight (normal, less than or equal to 0.5 mg/g), 
correlated well (r = .93, P less than or equal to .0001) with the preoperative hepatic T2 
measurements. The CT attenuation did not correlate with liver iron concentration. 
In a study done by Bakdekar et al32 it was shown that significant correlation exists 
between serum ferritin and CT liver density.
                                                     AIM  OF THE STUDY
 To determine the correlation between  serum ferritin and CT liver density in 
transfused Thalassemia major children.
MATERIALS AND METHODS
 Setting
Study was conducted in institute of child health and research centre-
Government Rajaji hospital,Madurai.
 Collaborarion Departments
The study was done in collaboration with Department of Radiology and 
Department of Biochemistry, Madurai.
 Ethical committee
Approval for the study was obtained from The Ethical committee of 
Govt.Rajaji Hospital. 
  Study design
         Prospective cross sectional analytical study
 Study period
          The study period was from January 2007 to June 2008  
 Sample size
A total of 30 children which included all Thalassemia major children enrolled 
in Institute of child health and research centre, Government Rajajii Hospital, 
Madurai.            
 Inclusion and Exclusion criteria:
All Thalassemia major children upto 12 years enrolled were included and none 
of the children were excluded.
PROCEDUR
Ethical approval was obtained.
 Relevant information was gathered using proforma.
 5 ml of venous sample was collected for serum ferritin estimation.
 Immunoenzymatic calorimetric method was used for quantitative determination of 
serum ferritin.
 The ferritin concentration in the sample was calculated based on a series of 
standard.
 The colour intensity was proportional to the ferritin concentration in the sample.
 CT abdomen was done to determine liver density.It was done on the same on the 
day of collection of blood sample for serum estimation.
 Five readings of liver density were determined in each lobe avoiding biliary tract, 
portal vein and porta hepatis.An average of these ten readings was designated as 
liver density of the patient. 
 Liver biopsy was done for four patients.
STATISTICAL  ANALYSIS:
       The information collected regarding all the selected cases were recorded 
in  a  Master  Chart.  Data  analysis  was  done  with  the  help  of  computer  using 
Epidemiological Information Package (EPI 2002).
Using this software,  frequencies,  percentages,  means,  standard deviations, 
chi  square, ‘p’  and  coefficient  of  correlation  values  were  calculated.  Kruskul 
Wallis  chi-square  test  was  used  to  test  the  significance  of  difference  between 
quantitative variables and Yate’s test for qualitative variables. A 'p' value less than 
0.05 is taken to denote significant relationship. If the coefficient of correlation (r) 
is more than 0.5 then the two variables are taken to be correlated.
OBSERVATIONS               TABLE 1 :  AGE DISTRIBUTION
Total number of children enrolled in the study were 30. 53.3% of the children 
were between 2-5 years of age.30% were between 6-8 years of age.10% were between 
9-10 years of age.6.7% were upto 2 years of age.











Upto 2 years 2 6.7
2-5 years 16 53.3
6-8 years 9 30



















53.4% of children studied were born of consanguinous parents.45.7% of children 
studied were born of nonconsanguinous parents.







53.3% of children studied had hemolytic facies. 46.7% of children did not have 
hemolytic facies.
TABLE 5 : REGULARITY OF TRANSFUSION




Out of 30 children studied 60% had regular transfusion and 40 % were not on 
regular transfusion. 




    Transfusions 
8-108 34.9 20.5
VI. C.T. liver
       Density
36-112 ng/ml 81.7 20.5
VII. Serum
      Ferritin
220-1750 HU 780 360
Number of transfusions ranged from 8-108.CT liver density ranged from 
36-112HU with a mean of 81.7HU.serum ferritin ranged from 220-1750ng/ml with a 
mean of 780 ng/ml.




Upto 250 (1) 38 38 -
251-500 (4) 36-60 48 9.8
501-750 (11) 66-89 77 7.7
751-1000 (9) 88-98 94.4 3.4
> 1000 (5) 102-112 106 4.2
Total 36-112 81.9 20.5
'p' 0.0001 Significant
Out of 30 children about 11 of the children had serum ferritin ranging from 501-750 ng/
ml and their liver density were between 66-89 HU. 9 children had serum ferritin 
between 751-1000 ng/ml and their liver density were between 88-98 HU.5 had serum 
ferritin more than 1000 ng/ml .Their liver density were between102-112 HU.4 children 
had serum ferritin between 251-500 ng/ml and liver density between 36-60 HU. 1 had 
serum ferritin less than 250 and had liver density of 38.   
TABLE 8 : CORRELATION OF COEFFICIENT BETWEEN SERUM 
FERRITIN AND CT LIVER DENSITY
Serum ferritin and
CT liver density
Coefficient of correlation 0.8526
Stastically significant correltion was found between serum ferritin and CT liver density.




















  12 children had 20-40 transfusions .Their mean CT liver density was 83. 82.8 childen 
had transfusions ranging from 8-20 and their mean CT liver density was 56.75.Another 
8 children had 41-60 transfusions .Their mean CT liver density was 96.78 HU. 2 of the 
children had more than 60 transfusions and their mean CT liver density of 105 HU.
TABLE 10 :  CORRELATION OF COEFFICIENT BETWEEN NUMBER OF 
TRANSFUSIONS AND CT LIVER DENSITY
Number of transfusions and CT 
liver density
Coefficient of correlation 0.7706
Stastically significant correlation was found between number of transfusions and CT 
liver density
TABLE 11 : SPLENOMEGALY
At the time of 
diagnosis




At the time of study
Mild 7 24.1
Moderate 18 62.1
Massive                   4 13.8
48.7% of children had mild splenomegaly, 41.4% had moderate and 10.3% had 
massive splenomegaly at the time of diagnosis.During present study ,62.1% had 
moderate splenomegaly,24.1% had mild splenomegaly and 4% had massive 
splenomegaly.
                                                            TABLE 12  
REGULARITY OF TRANSFUSION AND SPLEEN SIZE
Regularity of transfusion
Spleen size
No change Decrease Increase
No. % No. % No. %
Regular (18) 14 77.8 2 11.1 2 11.1
Irrregular (11) 2 18.2 - - 9 81.8
'p' 0.0002 Significant
               Out of 18 children who had regular transfusion 77.8% had no change in spleen 
size.11.1% had decrease in spleen size and another 11.1% had increase in spleen 
size.18.2% of 11 children who had irregular transfusion had no change in spleen size .
81.8% had increase in spleen size.
TABLE 13 : SPLENOMEGALY AND SERUM FERRITIN
Splenomegaly














b)At the time of study











Correlation between splenomegaly and serum ferritin was not stastically significant
















b)At the time of study











No correlation was established between spleenomegaly and CT liver density.
                                    
                                         DISCUSSION
           The creation of excessive iron stores associated with hemosiderosis is a major 
concern in individuals with beta Thalassemia major.They develop iron overload as a 
result  of  their  inability  to  excessive  iron  which  they  receive  via  multiple  blood 
transfusions.Increased iron absorption also contributes to iron excess.  Managing iron 
overload  in  Thalassemia  syndromes  require  a  reliable  assessment  of  excessive  iron 
overload and organ iron distribution. Measurement of hepatic iron concentration is the 
most quantitative, specific, and sensitive method for determining the body iron burden in 
patients with thalassemia major.
   Liver  biopsy  is  the  best  direct  means  of  assessing  iron  deposition,  permitting 
chemical measurement of the nonheme (storage) iron concentration and histochemical 
examination of the pattern of iron accumulation in hepatocytes and Kupffer cells as well 
as evaluation of the extent of inflammation, fibrosis, and cirrhosis. This direct method 
for assessing iron status have the disadvantages of being invasive procedures, with their 
attendant discomfort, lack of acceptability to patients, and, in the case of liver biopsy, 
risk. Several noninvasive means of measuring tissue iron stores are under development, 
including  determination  of  hepatic  magnetic  susceptibility,  computed  tomography 
(CT),and magnetic resonance imaging (MRI).CT abdomen was used in the present study 
as it is widely used and less expensive.
          A   total of 30  thalassemia major children were studied to determine the 
usefulness of CT  abdomen in determining iron overload.
Out  of  the  30  children  included  in  this  study  53.3  % were  in  the  age  group 
between  2-5 yearsof age,6.7% were upto 2 years of age,30% of children between 6-8 
years of age and 10% of children between 9-10 years of age.Mean age in the present 
study was 5.13 years.
          In a study done by Bhaswati et al4 it was found that 84.2% of the patients 
attending govt. hospitals were below 10 years of age as compared to only 48% attending 
the  Thalassemia  Society  in  the  same  age  group.  The  difference  was  found  to  be 
statistically significant (p<0.05).
          In 1973, a survey was done of the ages of 243 living patients with thalassemia 
major followed at 12 centers in the United States and Canada. Twenty-two percent were 
younger than 5 years and 2.1% were older than 25 years of age (mean 11.4 ± 6.7 [SD] 
years). In 1985, there were 303 patients at the same centers; 11% were younger than 5 
years and 7.9% were older than 25 years (mean 14.2 ± 7.3 years).
          66.7% of the children in the study were males and 33.3% were females.In the 
study done by Bhaswati et al has also found that in both govt. as well as NGO sector 
most of the thalassemic patients were male, being 58.6% and 72% respectively. 
          26.7% of children were born of first degree consanguinity and 26.7% of children 
were born of second degree consanguinity.53.3 % of children had hemolytic facies.
60% of children had regular transfusion whereas 40% of children had irregular 
transfusion.
          Number of transfusions given varied from 8-108.serum ferritin levels ranged from 
220-1750 nano gm/ml.Average serum ferritin was 780 ng/ml. CT liver density ranged 
from 36-112 HU and the mean CT liver density was 81.7 HU.
          Melody et al has done a study in 342 beta thalassemia patients and serum Ferritin 
levels ranged from 147 to 11 010 ng/mL (median, 1696 ng/mL).In the study done by 
Bakdekar et al  to study the correlation between serum ferritin and CT liver density, 
serum ferritin ranged from 1190 ng/ml to 15,000 ng/mland average serum ferritin level 
was 4289.4 ng/ml.CT liver density ranged from 72.3-119.8 hounsefield units and the 
mean was 98.
          Out of 30 children11 HU children had serum ferritin between 501-750 ng/ml had 
CT liver density between 66-89 HU.9 children had serum ferritin between 751-1000 ng/
ml and their liver density were between 88-98 HU.5 had serum ferritin more than 1000 
ng/ml  .Their  liver  density  were  between102-112  HU.4  children  had  serum  ferritin 
between 251-500 ng/ml  and liver  density  between 36-60 HU.  One child  had serum 
ferritin less than 250 and had liver density of 38.           
          Significant correlation was between serum ferritin and CT liver density and 
coefficient of correlation was 0.8526.
          Out of the 30 children studied 12 children had 20-40 transfusions .Their mean CT 
liver density wss 83. 82.8 childen had transfusions ranging from 8-20 and their  mean 
CT liver density  was 56.75.Another 8 children had 41-60 transfusions .Their mean CT 
liver density was 96.78 HU.2 of the children had more than 60 transfusions and their 
mean CT liver density was 105 HU.
           In a study done by Houang et al29 Computer tomographic (CT) scans of the liver 
were obtained in six thalassaemic patients with iron overload confirmed by liver biopsy. 
Mean CT values for the liver in individual  patients were linearly related to the iron 
content estimated by liver biopsy (correlation coefficient = 0.995).
Significant correlation was found between number of transfusions and CT liver 
density .Coefficient of correlation was  0.7706.
          In a study done by Guvader et al28 to evaluate CT in the assessment of iron 
overload the main results for liver attenuation (upper normal limit, 72 Hounsfield units) 
showed  that  despite  a  high  specificity  (0.96),  this  parameter  was  of  low sensitivity 
(0.63).
          In a study done by Howard et al26, hepatic computed tomography density ranged 
from 11 to 36 units (mean = 30)in 69 controls. Given an upper limit of normal of 36 
computed  tomography  units,  4  of  6  untreated  patients  with  hemochromatosis  had 
elevated hepatic computed tomography density.Hepatic computed tomography density 
correlated directly with serum ferritin (r = 0.72, p = 0.01). In 58 consecutive patients 
with clinical  or biochemical  evidence,  or  both,  of liver disease who underwent liver 
biopsy for diagnostic purposes, 0 of 52 patients with normal hepatic iron had an elevated 
hepatic computed tomography density as compared with 4 of 6 patients with excess iron 
(X2 = 35, p less than 0.001).
          In a study done by Bell et al25 Computed tomography (CT) was performed to 
estimate  the  density  of  the  hepatic  and  splenic  parenchyma  in  18  patients  with 
hemochromatosis. The mean CT density was 79 +/- 21 Hounsfield units compared with 
61 +/- 9 (p < 0.01) in 31 controls without hepatic disease. Increased density above 79 
Hounsfield units was found in eight patients out of 18 (44%). The highest density (125 
Hounsfield units) was found in a patient with a serum ferritin of 6500 micrograms/l. 
They found an  association between CT density and serum ferritin            (r = 0.72, p < 
0.01).
           Liver biopsy was done in 4 children.one child had hemosiderosis without 
evidence  of  cirrhosis.He  had  38  blood  transfusions  and  had  serum  ferritin  of  860 
ng/ml.His liver density was 96 HU.
           Two children had hemosiderosis with cirrhosis.One  had 108 transfusions His 
serum  ferritin  was  1182  ng/ml  and  liver  density  was  104  HU.Another  had  90 
transfusions.His serum ferritin was 1160 ng/ml and liver density was 112 HU.
           One child had hemosiderosis with periportal fibrosis in liver biopsy.There was no 
evidence of cirrhosis.She had 42 transfusions.Her serum ferrritin was 920 ng/ml and 
liver density was 96 HU. 
         Bonkovsky et al1 did a study and compared  the results of imaging procedures 
with those  of  other  noninvasive  techniques  and liver  biopsies  in  48 patients.  Serum 
ferritin and computed tomography or magnetic resonance scanning had 100% sensitivity 
in detecting hepatic iron overload more than fivefold above the upper limit of normal 
(greater than 10.7 mumol Fe/100 mg dry liver) but did not detect lesser degrees of iron 
overload reliably. Computed tomography and magnetic resonance imaging were more 
specific than ferritin (64% and 92% vs. 21%) in the detection of iron excess, more than 
five times the upper limit of normal.  It was concluded that computed tomography or 
magnetic resonance scanning as currently usually used is not cost-effective in routine 
evaluation  of  iron  overload,  although  these  imaging  procedures  may  play  a  role  in 
patients in whom liver biopsy is contraindicated. Because of their low cost and ready 
availability, serum ferritin remain the preferred screening study for iron overload.
           48.7% of children had mild splenomegaly, 41.4% had moderate and 10.3% had 
massive  splenomegaly  at  the  time  of  diagnosis.During  present  study,  62.1%  had 
moderate  splenomegaly,  24.1%  had  mild  splenomegaly  and  4%  had  massive 
splenomegaly.
           Out of 18 children who had regular transfusion 77.8% had no change in spleen 
size.11.1%  had  decrease  in  spleen  size  and  another  11.1%  had  increase  in  spleen 
size.18.2% of 11 children who had irregular transfusion had no change in spleen size .
81.8% had increase in spleen size.
                                    
                                    CONCLUSIONS
  1) Males are more commonly affected than females.
  2) 45.7% of thalassemia major children are born to non consanguinous parents.
  3) Only 60% of affected children are on regular transfusions.
  4) Significant correlation exists between serum ferritin and CT liver density.
  5) Children with cirrhosis had serum ferritin more than 1000 ng/ml and CT liver 
density more than 100 HU.
6) Significant  correlation  exists  between  CT  liver  density  and  number  of 
transfusions.
  7) Spleen size regresses with regular transfusion.
  8) No correlation exists between serum ferritin and splenomegaly.
  9) There is no correlation between CT liver density and splenomegaly.
                               
                                 
LIMITATIONS OF THE STUDY
 Small sample size.
 Liver biopsy being an invasive procedure consent could  be obtained only 
for 4 cases.
 Quantitative iron estimation in liver biopsy could not be done.
                                        RECOMMENDATIONS
 1) CT  may be used  for estimation of iron overload in thalassemia major children.
 2) To improve the regularity of transfusions day care facility should be established.
3) Antenatal  screening  should  be  done  for  all  mothers  who  are  NESTROF  test 
positive irrespective of consanguinity.
4) Iron chelation should be started at serum ferritin less than 1000ng/ml in contrast 
to  earlier  studies  and CT liver  density  less  than  100 HU to  prevent  cirrhosis 
liver.Further studies are needed.
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ABBREVIATIONS
          1) CT - Computed Tomography
2) MRI - Magnetic Resonance Imaging
3) HU - Hounsfield Unit
4) SD - Standard Deviation
5) Hb - Hemoglobin
                           
